KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNTech SE (BNTX) Total Debt (2018 - 2025)

BioNTech SE's Total Debt history spans 8 years, with the latest figure at $409.4 million for Q4 2025.

  • On a quarterly basis, Total Debt fell 74.29% to $409.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $409.4 million, a 74.29% decrease, with the full-year FY2025 number at $397.4 million, down 75.05% from a year prior.
  • Total Debt hit $409.4 million in Q4 2025 for BioNTech SE, down from $698.4 million in the prior quarter.
  • Over the last five years, Total Debt for BNTX hit a ceiling of $11.1 billion in Q2 2022 and a floor of $37.3 million in Q3 2022.
  • Historically, Total Debt has averaged $1.2 billion across 5 years, with a median of $437.9 million in 2025.
  • The widest YoY moves for Total Debt: up 838.43% in 2023, down 98.3% in 2023.
  • Tracing BNTX's Total Debt over 5 years: stood at $1.6 billion in 2021, then tumbled by 48.42% to $807.2 million in 2022, then crashed by 39.49% to $488.5 million in 2023, then skyrocketed by 226.02% to $1.6 billion in 2024, then plummeted by 74.29% to $409.4 million in 2025.
  • Business Quant data shows Total Debt for BNTX at $409.4 million in Q4 2025, $698.4 million in Q3 2025, and $164.1 million in Q2 2025.